Northwestern University Feinberg School of Medicine

Department of Dermatology

Clinical Trials

Clinical and Outcomes Research under the direction of the Department of Dermatology is conducted at the Northwestern University Feinberg School of Medicine, Ann & Robert H. Lurie Children's Hospital of Chicago, and Northwestern Lake Forest Hospital dermatology clinics.

For more information about the research or participation, please call our office at 312-503-5944.

Trials
DERMATOLOGY TISSUE ACQUISITION AND REPOSITORY
Northwestern University’s Department of Dermatology is collecting skin, hair, nail, blood, saliva, skin and/or buccal swabs, and mucous membrane(part of your skin which lines body passages and cavities such as the inside of your mouth or nose), and ot…
Northwestern University’s Department of Dermatology is collecting skin, hair, nail, blood, saliva, skin and/or buccal swabs, and mucous membrane(part of your skin which lines body passages and cavities such as the inside of your mouth or nose), and other tissue samples for use in a biorepository. By operating this biorepository, the Department of Dermatology hopes to develop a better understanding of skin diseases (meaning the knowledge about how cells in the skin behave and react to medical treatments) among researchers at Northwestern University and other approved researchers. This basic knowledge is expected to help the development of more effective patient care and new treatment methods.
-Having specimens collected as part of a standard of care procedure;
-Have a skin disease which researchers want samples of in order to further understand
it; or
-Qualify as a healthy volunteer whose samples researchers can use as control samples
for research.
West, Dennis PWest, Dennis P
  • Map it 676 N. St. Clair St.
    Chicago, IL
STU00009443
More Info

For more information on this study please contact us:

Pease, David 312 503 5901
Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)
To evaluate the safety and effectiveness of the topical ointment (cream), SGX301, in combination with light therapy in patients with cutaneous T-cell lymphoma.
Must be 18 years of age or older, with a clinical diagnosis of Cutaneous T- Cell Lymphoma, Myucosis Fungoides, Stage IA. Stage IB, or Stage IIA, and willing to refrain from sunbathing for duration of the study.
Guitart, JoanGuitart, Joan
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT02448381 STU00200530
More Info

For more information on this study please contact us:

Serrano, Linda 312 503 5903
Observational US Study Assessing Outcomes, Treatment Patterns, AEs, QOL in MF-CTCL Patients and Treated With Valchlor
The purpose of this study is to better understand: the use of Valchlor®; the disease of MF-CTCL; the health outcomes in patients treated with Valchlor® under care by your doctor.
Adult patients currently being treated with Valchlor®, for the treatment of mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL) and able to sign an informed consent form without assistant from others.
Guitart, JoanGuitart, Joan
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT02296164 STU00200362
More Info

For more information on this study please contact us:

Serrano, Linda 312 503 5903
AAD-PEPR: Asthma and Atopic Dermatitis Validation of PROMIS Pediatric Instruments
The purpose of this study is to validate patient-reported outcomes (PRO) measures in three existing asthma intervention trials as well as a large group of itch-specific pediatric skin conditions, primarily focusing on a…
The purpose of this study is to validate patient-reported outcomes (PRO) measures in three existing asthma intervention trials as well as a large group of itch-specific pediatric skin conditions, primarily focusing on atopic dermatitis (AD, or eczema). The study will look at how well Patient Reported Outcomes Measurement Information System (PROMIS) tools uncover meaningful changes in disease status as well as build a list of items relating to pediatric skin diseases and a PRO model for signs and symptoms of skin disease.
Paller, AmyPaller, Amy
  • Map it 225 E. Chicago Ave.
    Chicago, IL
  • Map it 676 N. St. Clair St.
    Chicago, IL
STU00202292
More Info

For more information on this study please contact us:

Zebda, Rema 312 227 6484
(CIRB) A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients with Dermatomyositis
Dermatomyositis is a rare, progressively debilitating disorder that affects the muscle (causing weakness) and skin (causing a rash) in most affected patients. Additionally, it can also in…
Dermatomyositis is a rare, progressively debilitating disorder that affects the muscle (causing weakness) and skin (causing a rash) in most affected patients. Additionally, it can also involve multiple bodily systems including the lungs, joints, gut and heart. The purpose of this study is to learn more about how safe and effective IMO-8400 is, including what impact it may have on the cutaneous (skin) manifestations of dermatomyositis, how well the body tolerates IMO-8400, what the body does to IMO-8400, and what IMO-8400 does to the body in adult patients with dermatomyositis with active skin and muscle disease who are not well controlled on current therapy.
Laumann, Anne ELaumann, Anne E
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT02612857 STU00202049
More Info

For more information on this study please contact us:

Ali, Yasmeen 312 503 5906
A Phase 1 Dose-Ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 following Local Intratumoral and Subcutaneous Injection in Patients with Cutaneous T-cell Lymphoma (CTCL), Mycosis Fungoides (MF) Sub-Type
The main goal of this study is to test the safety and tolera…
The main goal of this study is to test the safety and tolerability of multiple injections subcutaneously (under the skin) or an IV infusion of MRG-106, in patients with CTCL, MF subtype.
Diagnosed with CTCL, MF subtype, Stage 1,2 or 3, have at least one lesion that is a raised plaque or tumor, have not had an adequate response to other CTCL therapies, and are capable of self care.
Guitart, JoanGuitart, Joan
  • Map it 676 N. St. Clair St.
    Chicago, IL
STU00201702
More Info

For more information on this study please contact us:

Serrano, Linda 312 503 5903
Defining the Skin and Blood Biomarkers of Ichthyosis
Ichthyosis is a group of genetic skin disorders that present with dry, thickened, scaly, or flaky skin. As of today, there is no cure or treatment. Doctors can only treat the dry skin with different types of emollients to soften the scale. A deeper…
Ichthyosis is a group of genetic skin disorders that present with dry, thickened, scaly, or flaky skin. As of today, there is no cure or treatment. Doctors can only treat the dry skin with different types of emollients to soften the scale. A deeper understanding of this disease is required to develop better treatments. There are different types of cells and cell-produced signals (biomarkers) that are being studied in order to help find these new treatments. Looking at biomarkers has been successful in helping us to understand other skin disorders better. The purpose of this study is to determine which blood and skin biomarkers characterize ichthyosis in children.
Subjects (1 year to 60 years of age) with Autosomal Recessive Congenital Ichthyosis (ARCI), which includes lamellar Ichthyosis, Netherton Syndrome, or other ichthyosis subtypes will be enrolled.
Healthy control subjects will be enrolled for either a blood sample or skin sample, and/or tape strip samples.
Paller, AmyPaller, Amy
  • Map it 1131 Techny Rd.
    Northbrook, IL
  • Map it 225 E. Chicago Ave.
    Chicago, IL
  • Map it 676 N. St. Clair St.
    Chicago, IL
STU00203051
More Info

For more information on this study please contact us:

Patel, Krishna 312 227 6486
Joint Complaints in Children with Harlequin Ichthyosis: A Study to Assess for Comorbidity
The goal of this study is to understand the pattern of joint pain and what pain management options or treatments have worked for individuals with joint disease related to Harlequin Ichthyosis (HI). Participatio…
The goal of this study is to understand the pattern of joint pain and what pain management options or treatments have worked for individuals with joint disease related to Harlequin Ichthyosis (HI). Participation in the study will involve completing a one-time survey administered through letter mailing, emailing, link using an online survey, or in person at the Lurie Children’s Dermatology Clinic. The survey will take about 15-30 minutes.
Confirmed diagnosis of Harlequin Ichthyosis (HI) and have complaints of joint pain, difficulty walking, swelling or other similar issues with your muscles and bones.
Paller, AmyPaller, Amy
  • Map it 1131 Techny Rd.
    Northbrook, IL
  • Map it 225 E. Chicago Ave.
    Chicago, IL
  • Map it 676 N. St. Clair St.
    Chicago, IL
STU00203185
More Info

For more information on this study please contact us:

Murphrey, Morgan 312 503 5917
Defining The Skin and Blood Biomarkers of Pediatric Atopic Dermatitis
Atopic dermatitis (AD), also called eczema, is a disease in which the skin is dry and scaly with severe itching that may continue despite treatment. A deeper understanding of this disease is required to develop new and better treat…
Atopic dermatitis (AD), also called eczema, is a disease in which the skin is dry and scaly with severe itching that may continue despite treatment. A deeper understanding of this disease is required to develop new and better treatments. There are different types of cells and cell-produced signals (biomarkers) that have been found in adults with AD. Nevertheless, there may be significant differences between AD in children versus adults. The purpose of this study is to determine which blood and skin biomarkers characterize AD in children by looking at the blood and skin biomarkers of children with AD and children without AD.
This study will enroll children ages 0 months to 17 years to collect blood, skin, saliva and tape strip samples in order to look at biomarkers related to AD. Children who have or have not been diagnosed with AD or an atopic condition, such as allergies or asthma.
Paller, AmyPaller, Amy
  • Map it 1131 Techny Rd.
    Northbrook, IL
  • Map it 225 E. Chicago Ave.
    Chicago, IL
  • Map it 676 N. St. Clair St.
    Chicago, IL
STU00203272
More Info

For more information on this study please contact us:

Patel, Krishna 312 227 6486
A Double Blind, Randomized, Vehicle Controlled, Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients with the Mycosis Fungoides (MF) Form of Cutaneous T-Cell Lymphoma (CTCL)
The main goal of this study is to test the …
The main goal of this study is to test the efficacy and safety of topical Naloxone for itching in patients with MF.
21 years of age or older with a diagnosis of mycosis fungoides (MF) with itching present on a daily basis for more than one month and willing to fill out a diary for 7 days to provide severity of itch before enrollment.
Guitart, JoanGuitart, Joan
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT02811783 STU00203078
More Info

For more information on this study please contact us:

Serrano, Linda 312 503 5903
A Pilot Study to Evaluate the Efficacy and Safety of Secukinumab in the Treatment of Patients with Ichthyoses Sub-Study: A Multicenter Study with a Randomized, Double-Blind, Placebo-Controlled Period, Followed by an Open-Label Maintenance Dosing Period to Evaluate the Efficacy and Safety of Secukinumab in Patients with Ichthyoses
This is a year-long study which will require monthly visits to the study site. The first four months will be double blind (you may receive either the study medication or placebo), then the remainder of the year participants will receive monthly injections of study medication.
Participants must be 18 years of age or older, with a confirmed diagnosis of Autosomal Recessive Congential Ichthyosis (Lamellar Ichthyosis, Congential Ichthyosiform Erythroderma), Epidermolytic Ichthyosis, or Netherton's Syndrome, and at least moderate redness of the skin.
Paller, AmyPaller, Amy
  • Map it 676 N. St. Clair St.
    Chicago, IL
STU00202022
More Info

For more information on this study please contact us:

Wu, Benedict 312 503 5907
A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients with Advanced Cutaneous Squamous Cell Carcinoma
The purpose of this study is to test the effects of REGN2810 in patients with advanced cutaneous squamous cell carcinoma (CSCC). The researchers wil…
The purpose of this study is to test the effects of REGN2810 in patients with advanced cutaneous squamous cell carcinoma (CSCC). The researchers will study the effects of REGN2810 and how long the effects last. The information will help researchers understand if REGN2810 could be used for the treatment of advanced CSCC. REGN2810 is an investigational drug. “Investigational” means that it is not approved by the US Food and Drug Administration (FDA).
Patients with unresectable locally advanced cutaneous squamous cell carcinoma (CSCC). Patients are required to have disease that is considered inoperable or to have medical contraindication to surgery or radiation, or have not achieved disease control with these treatments.
Alam, MuradAlam, Murad
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT02760498 STU00202715
More Info

For more information on this study please contact us:

Wu, Benedict 312 503 5907
A Randomized, Bilateral Comparison, Vehicle-Controlled, Safety and Tolerability Study of Topical PAT-001 for the Treatment of Congenital Ichthyosis
Congenital ichthyosis is a large and varied family of inherited skin disorders characterized by dry, scaling skin that may be thickened or very thin. Thi…
Congenital ichthyosis is a large and varied family of inherited skin disorders characterized by dry, scaling skin that may be thickened or very thin. This clinical trial seeks to investigate the safety and tolerability of a topically applied ointment (PAT-001) as a treatment for congenital ichthyosis
Subjects must be at least twelve years old with clinically confirmed diagnosis of either lamellar ichthyosis or X-linked ichthyosis
Paller, AmyPaller, Amy
  • Map it 1131 Techny Rd.
    Northbrook, IL
  • Map it 225 E. Chicago Ave.
    Chicago, IL
STU00204653
More Info

For more information on this study please contact us:

Patel, Krishna 312 227 6486
A Double-Blind, Randomized, Placebo Controlled, Parallel Dose Study to Evaluate the Safety and Efficacy of CTP-543 in Adult Patients with Moderate to Severe Alopecia Areata
Alopecia areata is an autoimmune disorder characterized by patches of non-scarring alopecia affecting scalp and body hair. This…
Alopecia areata is an autoimmune disorder characterized by patches of non-scarring alopecia affecting scalp and body hair. This research study will look at the investigational medication compared to a placebo when given to research subjects with alopecia areata twice-daily for a total of 24 weeks. The main purpose is to determine if the investigational medication causes hair to regrow, and to see if taking the investigational medication is safe. Other purposes of the study are to determine the amount of investigational medication in the blood after dosing, and to determine how you and your doctor feel about your alopecia areata during the study. The investigational medication is a modified version of another drug called Jakafi, which is approved by the FDA for other uses, but not for alopecia areata.
At least 50% hair loss on your head due to alopecia areata with a current episode of at least 6 months. You are required to be between the ages of 18 and 65 to participate in this study. You will not be able to participate if you are currently undergoing treatment with another drug or with other treatments that might affect your hair regrowth or if you are taking medicines that weaken your immune system.
Colavincenzo, Maria LColavincenzo, Maria L
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT03137381 STU00204314
More Info

For more information on this study please contact us:

Orrell, Kelsey 312 503 5912
Corrona Psoriasis Registry
The main purpose of the Corrona Psoriasis registry is to learn more about psoriasis, how doctors treat psoriasis, how well medications and treatments work, and the safety of those treatments.
To be eligible, you need to be 18 years of age or older, have been diagnosed with psoriasis by a dermatologist, and have started on or switched to a systemic biologic psoriasis treatment within the previous 12 months by a Northwestern dermatologist.
Amin, AhmadAmin, Ahmad
  • Map it 676 N. St. Clair St.
    Chicago, IL
STU00203552
More Info
psoriasis

For more information on this study please contact us:

Thiede, Rebecca 312 503 5902
Gene Expression and Biomarker Profiling of Keloid Skin Sub-Study: A Pilot Trial of Keloid Genomic Profiling Using RNAseq
Northwestern’s Department of Dermatology is performing a research study to better understand the causes of keloid scars. Keloid scars are solid tissue overgrowths that tend to d…
Northwestern’s Department of Dermatology is performing a research study to better understand the causes of keloid scars. Keloid scars are solid tissue overgrowths that tend to develop after trauma to the skin.
Subjects who are 18 years of age or older. Have no history of keloids or have a keloid on the earlobe or on another area of your body that either has not been treated or if treated, the treatment took place more than 6 months ago.
Kundu, Roopal VashiKundu, Roopal Vashi
  • Map it 676 N. St. Clair St.
    Chicago, IL
STU00203462
More Info
keloid

For more information on this study please contact us:

Ali, Yasmeen 312 503 5906
An International, Multicenter, Randomized, Double-Blind, Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS).
Epidermolysis bullosa simplex (EBS) is a rare disorder that causes the skin to be…
Epidermolysis bullosa simplex (EBS) is a rare disorder that causes the skin to be fragile. It is passed down from one or both parents, and the main signs are painful blisters that can become infected. The purpose of this study is to assess the safety and efficacy of an investigational topical (applied to the skin) ointment called Diacerein 1% for people with EBS. Enrollment in the study can be for up to 22 weeks and it will involve about 8 study visits to the site.
At least 4 years of age with a clinical diagnosis and genetic mutation documented for epidermolysis bullosa simplex (EBS). Have EBS lesions that are greater than or equal to 2% body surface areas. The lesions need to be either generalized on the body or localized to the feet and palms. Patients with EBS lesions that are infected will be ineligible.
Paller, AmyPaller, Amy
  • Map it 225 E. Chicago Ave.
    Chicago, IL
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT03154333 STU00205467
More Info

For more information on this study please contact us:

Zebda, Rema 312 227 6484
(CIRB) Study 205050: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Mepolizumab Administered Subcutaneously in Subjects with Moderate to Severe Atopic Dermatitis
This research is for subjects with moderate to severe atopic d…
This research is for subjects with moderate to severe atopic dermatitis, a skin condition also known as atopic eczema. The purpose of this study is to see how well subcutaneous doses of an the investigational drug or placebo works in possibly treating moderate to severe atopic dermatitis and to test its safety.
Between 18 -70 years of age {var DanaWithTmpArray = new Array(); with (DanaWithTmpArray[0] = iagnosis of} AD ≥ 2 years.
Silverberg, JonathanSilverberg, Jonathan
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT03055195 STU00204658
More Info

For more information on this study please contact us:

Orrell, Kelsey 312 503 5912
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients from 6 to Less than 18 Years of Age with Moderate-to-Severe Plaque Psoriasis
Plaque psoriasis is a condition in which skin cells build up and itchy, dry patches and…
Plaque psoriasis is a condition in which skin cells build up and itchy, dry patches and scales. The purpose of this study is to see how safe an investigational drug called ixekizumab for people with plaque psoriasis. This study is being done in two groups to understand how well ixekizumab will work to help people with plaque psoriasis. This study is also being done to get more information about the drug’s safety.
Between the ages of 6 and 18 years of age with a diagnosis of moderate-to-severe plaque-type psoriasis for at least 6 months.
Paller, AmyPaller, Amy
  • Map it 1131 Techny Rd.
    Northbrook, IL
  • Map it 225 E. Chicago Ave.
    Chicago, IL
STU00205002
More Info

For more information on this study please contact us:

Patel, Krishna 312 227 6486
(xIRB) A Randomized, Double-Blind, Dose-Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo
Vitiligo is a condition in which pigment is lost from areas of the skin and results in whitish patches. This study will test the ability of a study drug to suppress the immune attack on the p…
Vitiligo is a condition in which pigment is lost from areas of the skin and results in whitish patches. This study will test the ability of a study drug to suppress the immune attack on the pigment producing cells in the skin and observe whether the pigment (normal skin color) in the skin can recover. The total duration of study participation is up to 120 weeks, which includes screening, three treatment parts, and safety follow‐up.
Diagnosed with Vitiligo by a dermatologist, between 18‐75 years of age, not currently on any light treatment, never used bleaching therapies in the past, and have de‐pigmented areas present on the face and non‐facial areas.
Kundu, Roopal VashiKundu, Roopal Vashi
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT03099304 STU00204998
More Info

For more information on this study please contact us:

Thiede, Rebecca 312 503 5902
A Randomized, Double-Blind, Placebo-Controlled Study To Investigate The Efficacy And Safety Of Dupilumab Monotherapy In Patients ≥12 TO <18 Years Of Age, With Moderate-To-Severe Atopic Dermatitis
Atopic dermatitis is a type of swelling of the skin. It results in itchy, red, swollen and cracked skin…
Atopic dermatitis is a type of swelling of the skin. It results in itchy, red, swollen and cracked skin. Clear fluid may come from the areas where there is atopic dermatitis, which often gets thicker over time. This research study is being conducted to determine how effective dupilumab, an investigational drug, is and how safe it is in reducing the signs and symptoms of eczema for those suffering with it. The duration of the study for each patient is approximately 28 weeks.
The study population will include patients ≥12 years to <18 years of age with moderate-to-severe atopic dermatitis whose disease cannot be adequately controlled with topical medications or for whom topical treatment is medically inadvisable
Paller, AmyPaller, Amy
  • Map it 1131 Techny Rd.
    Northbrook, IL
  • Map it 225 E. Chicago Ave.
    Chicago, IL
STU00205501
More Info

For more information on this study please contact us:

Zebda, Rema 312 227 6484